Our Perspectives
Cerberus Ventures partners with visionary founders and consequential companies looking to move the world forward.
No items found.
Oops! Something went wrong while submitting the form.
PrismML Steps Out of Stealth
Most efficiency gains in AI are incremental. PrismML is going after something more fundamental.
PrismML Launches World's First 1-Bit AI Model to Redefine Intelligence at the Edge
PrismML, a pioneer in high-performance AI models, today emerged from stealth to introduce the world's first commercially viable 1-bit large language models, built on groundbreaking research developed at Caltech. PrismML's sweeping goal is to enable a future where powerful AI can run locally, efficiently, securely, and faster, and where datacenter buildouts can do more with fewer resources and avoid ballooning energy costs.
Announcing Our Investment in Virchow Medical
We’re proud to partner with Virchow to expand the availability of clinically-sourced genomic data.
Virchow Raises $4 Million to Advance Biopsy Specimen Stewardship and Expand Access to Precision Oncology
Cerberus Ventures leads financing alongside five physician users of Virchow’s biopsy technologies.
Why Now is the Time to Build in TechBio
Cerberus Ventures' Chenny Zhang joined a TechBio investor panel at the LSX Investival Showcase in Miami alongside a group of fellow investors to discuss the new era of tech-driven biology.
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions
Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the first patient has been dosed in the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101, the company’s lead investigational program for the treatment of obesity. SYNT-101 is designed as a once-daily oral pill that redirects nutrient absorption past the small intestine’s duodenum, mimicking the effects of gastric bypass surgery.
CES 2026: Quick Takes From the Floor
At CES 2026, we met with founders, operators, and platform builders across the technology ecosystem and here are a few quick takeaways.
The Year Ahead: Our 2026 Outlook
2025 was a year defined by rapid innovation and a shifting geopolitical landscape. Artificial intelligence advanced at breakneck speed, reshaping industries, economies, and even the foundations of society. The race toward harnessing artificial intelligence has become one of the defining competitions of our era.
2025 Highlights
2025 was a big year for Cerberus Ventures. We backed incredible companies, celebrated portfolio milestones, and so much more.
The Build: Nudge Security
Cerberus Ventures’ Director Morgan Mahlock speaks with Russell Spitler, Co-Founder and CEO of Nudge Security, a SaaS and AI platform for the modern workforce.
Red Queen Bio Bringing AI into the Lab
Working with OpenAI, Red Queen Bio is helping to bring AI into the lab. Their collaboration is showing how AI can move beyond analysis and into real biological experimentation, with the potential to unlock new approaches to science itself.
Announcing Our Investment in Nudge Security
We are excited to share our recent Series A investment in Nudge Security, a company looking to redefine cybersecurity for the modern workforce. The company’s mission is to automate the guardrails at the Workforce Edge by guiding employees toward approved applications and AI tools, enhancing the pace of business and minimizing friction.
Nudge Security Raises $22.5M Series A to Secure Workforce AI and SaaS
Nudge Security, the leading innovator in SaaS and AI security governance, today announced Series A funding of $22.5 million led by Cerberus Ventures with participation from existing investors Ballistic Ventures, Forgepoint Capital, and Squadra Ventures. With the new funding, Morgan Mahlock of Cerberus Ventures will join the Nudge Security board.
Red Queen Bio Launches
Today, we are launching Red Queen Bio, an AI biosecurity company. The Red Queen hypothesis describes a species’ co-evolution with ever-evolving opponents.
ChipStack is Joining Cadence
ChipStack announced they signed a definitive agreement to join Cadence, a world leader in electronic design automation.
Ansa Biotechnologies Secures $54.4 Million in Series B Financing to Redefine How Scientists Access Synthetic DNA
Ansa Biotechnologies, Inc., a trusted partner for DNA synthesis, today announced that it has closed $45.2 million and secured commitments for an additional $9.2 million as part of an oversubscribed series B financing round.
No Results Found
Try adjusting your search
Footnotes
Disclaimer
Information included herein represents the views and beliefs of Cerberus. There can be no guarantee Cerberus Ventures will achieve its investment objectives or that partnering with Cerberus Ventures will ensure or contribute to the success of any company. Statements included herein are based upon information reasonably available to Cerberus as of the date included. However, the inclusion of such statements shall not create any implication that the information contained herein is correct in all respects, including as of any time subsequent to the date thereof, and Cerberus does not undertake any obligation to update such information at any time after such date. For more information about Cerberus, please visit www.cerberus.com.